|
Real-time Estimate
Cboe BZX
12:18:54 25/09/26 am AEST
|
5-day change | 1st Jan Change | ||
| 152.82 USD | +0.96% |
|
+0.83% | +23.95% |
| 18/09 | Dr. Reddy's Confirms License for Gilead's Yearly-Once HIV Drug; Shares Up 2% | MT |
| 17/09 | Gilead Sciences Insider Sold Shares Worth $432,646, According to a Recent SEC Filing | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Other Pharmaceuticals
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 188B | - | ||||
| 1,026B | |||||
| 649B | - | ||||
| 468B | |||||
| 352B | |||||
| 271B |
- Stock Market
- Stocks
- GILD Stock
- Charts Gilead Sciences, Inc.
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
